> Protalix BioTherapeutics wrapped up a 16-person trial of its cystic fibrosis candidate alidornase alfa. The trial linked the recombinant form of human deoxyribonuclease I to a 3.4 point mean absolute increase in ppFEV1 over baseline. That compares to the 4.1 point increase Protalix posted when it presented interim data on 13 patients in January. Release
> Argenx began a phase 2 trial of ARGX-110 in patients with relapsed or refractory cutaneous T-cell lymphoma. The small study is expected to deliver interim data by the end of the year, with top-line results due to follow in the second half of 2018. Argenx is also developing ARGX-110, a CD70-targeting antibody, as a treatment for acute myeloid leukaemia. Statement
> Abivax branched out into research against Zika virus. The French biotech decided to push ahead with research in the area after several small molecules from its library showed activity against the virus. Abivax will now assess the potential of the molecules to inhibit the damage Zika virus causes to neuronal stem cells. Release
> Cellectis revealed its is considering an IPO for its plant science unit, Calyxt. The move would see the immuno-oncology player sell a minority stake in the business. At this stage, it is unclear if the IPO will go ahead and, if it does, on what terms. Statement
> Erytech Pharma filed to raise €70.5 million ($74.8 million) through a private placement. The French drug developer wants the money to fund a planned phase 3 of eryaspase in pancreatic cancer. Shares in Erytech are up 88% so far this year on the strength of phase 2b data it presented last month. Release
> Sensorion appointed Nawal Ouzren as its CEO. Ouzren landed the gig after rising through the ranks at Baxter and, following the spinoff and takeover, Baxalta and Shire. France’s Sensorion hopes the appointment will help it to develop internationally. Statement